Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Clinical trial NCT06960395 · RECRUITING

Trial details

NCT number: NCT06960395
Sponsor: Vir Biotechnology, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Malignancies EGFR Positive Solid Tumors EGFR

Start date: 2025-07-22
Primary completion: 2029-08-01
Enrollment: 450

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.